Opendata, web and dolomites

EU-PEARL SIGNED

EU Patient- cEntric clinicAl tRial pLatform

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EU-PEARL" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA 

Organization address
address: PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA
city: BARCELONA
postcode: 8035
website: http://www.vhir.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 26˙238˙047 €
 EC max contribution 12˙004˙952 € (46%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2023-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) coordinator 1˙987˙375.00
2    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 899˙875.00
3    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 835˙875.00
4    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 831˙375.00
5    EATRIS ERIC NL (AMSTERDAM) participant 743˙625.00
6    UNIVERSITA VITA-SALUTE SAN RAFFAELE IT (MILANO) participant 734˙250.00
7    THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA BE (STROMBEEK-BEVER) participant 664˙625.00
8    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 619˙750.00
9    KING'S COLLEGE LONDON UK (LONDON) participant 612˙077.00
10    CUSTODIX NV BE (SINT-MARTENS-LATEM) participant 605˙125.00
11    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 539˙000.00
12    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 459˙250.00
13    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 426˙875.00
14    BERRY CONSULTANTS LLP UK (ABINGDON) participant 319˙125.00
15    BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL DE (LANGEN) participant 317˙625.00
16    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 277˙375.00
17    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 274˙750.00
18    DOCUMENTAL OU EE (TALLINN) participant 195˙250.00
19    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 186˙375.00
20    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 145˙250.00
21    EUROSCAN INTERNATIONAL NETWORK EV DE (KOLN) participant 117˙500.00
22    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 114˙625.00
23    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 98˙000.00
24    ALLERGAN LIMITED UK (MARLOW) participant 0.00
25    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
26    CHILDREN'S TUMOR FOUNDATION US (NEW YORK) participant 0.00
27    GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION US (NEW YORK) participant 0.00
28    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
29    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
30    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
31    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
32    OTSUKA NOVEL PRODUCTS GMBH DE (MUNCHEN) participant 0.00
33    PFIZER LIMITED UK (SANDWICH) participant 0.00
34    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
35    SPRINGWORKS THERAPEUTICS INC US (STAMFORD CT) participant 0.00
36    TEVA PHARMACEUTICAL INDUSTRIES LIMITED IL (PETACH TIVKA) participant 0.00

Map

 Project objective

EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs. Patient-centric data and knowledge sharing have the potential to accelerate the development of new treatments and reduce the operational costs of clinical trials. EU-PEARL will improve clinical effectiveness, patients’ satisfaction and societal access to timely and affordable medicines and it will shape the clinical trials of the future. This will change the industry paradigm from competition to cooperation in four disease areas and provide the framework for designing IRPs in other disease areas. The main objectives of EU-PEARL are: (1) To create a reusable, accessible and sustainable modular IRP for the design and execution of patient-centric, cross- company IRP in any disease area with unmet needs; (2) To set up the open, dynamic, patient inclusive IRP governance structure that will manage the appropriate regulatory, ethical, legal, statistical and data utilisation requirements of the IRP; (3) To disseminate and exploit the EU-PEARL paradigm through the provision of the necessary common tools, procedures, expertise and operational skills working to the highest scientific, regulatory and ethical standards and best practices, developed jointly by public and industry partners in a consensus-based approach; and (4) To create trial-ready IRP networks in the four disease areas of Major Depressive Disorder (MDD), Tuberculosis (TB), Non-Alcoholic Steatohepatitis (NASH) and Neurofibromatosis (NF).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EU-PEARL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EU-PEARL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More